{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T23:07:45Z","timestamp":1774566465316,"version":"3.50.1"},"reference-count":130,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2012,1,17]],"date-time":"2012-01-17T00:00:00Z","timestamp":1326758400000},"content-version":"vor","delay-in-days":4002,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2001,2]]},"abstract":"<jats:p>As a result of numerous clinical trials and meta\u2010analyses supporting the superior efficacy and relative safety of low\u2010molecular\u2010weight heparins (LMWHs) compared with unfractionated heparin (UFH), LMWHs are emerging as the antithrombotic agents of choice for the prevention and treatment of deep vein thrombosis and pulmonary embolism. In addition, data indicate that enoxaparin given with low\u2010dosage aspirin is more effective than UFH in treating acute coronary syndromes. Anti\u2010Xa activity can be used as a biologic marker of LMWH activity. Because of the more predictable anticoagulant response to subcutaneous administration of LMWHs compared with UFH, routine monitoring of anti\u2010Xa activity in clinically stable adults with uncomplicated disease is not recommended. Because the optimal dosage of LMWHs has not been established for patients with renal insufficiency or extremes of body weight, during pregnancy, or for children, anti\u2010Xa activity monitoring may be warranted in these subsets.<\/jats:p>","DOI":"10.1592\/phco.21.2.218.34112","type":"journal-article","created":{"date-parts":[[2004,6,7]],"date-time":"2004-06-07T05:03:57Z","timestamp":1086584637000},"page":"218-234","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":108,"title":["Dosing and Monitoring of Low\u2010Molecular\u2010Weight Heparins in Special Populations"],"prefix":"10.1002","volume":"21","author":[{"given":"Beth A.","family":"Duplaga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina W.","family":"Rivers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edith","family":"Nutescu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,1,17]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1072-7515(98)00255-5"},{"key":"e_1_2_1_3_2","volume-title":"Martindale: the complete drug reference, 32nd ed","author":"Parfitt K.","year":"1999"},{"issue":"3","key":"e_1_2_1_4_2","first-page":"5","article-title":"Production and chemical processing of low molecular weight heparins","volume":"25","author":"Linhardt R.J.","year":"1999","journal-title":"Semin Thromb Hemost"},{"key":"e_1_2_1_5_2","volume-title":"Innohep (tinzaparin sodium injection) package insert","author":"Pharma DuPont","year":"2000"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199709043371007"},{"issue":"4","key":"e_1_2_1_7_2","first-page":"35","article-title":"Low molecular weight heparins: practical considerations","volume":"34","author":"Kessler C.M.","year":"1997","journal-title":"Semin Hematol"},{"key":"e_1_2_1_8_2","first-page":"364","article-title":"Effectiveness and safety of low molecular weight heparins (LMWH) in the prevention of venous thromboembolism (VTE)","volume":"74","author":"Kakkar V.V.","year":"1999","journal-title":"Thromb Haemost"},{"issue":"3","key":"e_1_2_1_9_2","first-page":"51","article-title":"Pharmacokinetics of low\u2010molecular\u2010weight heparins in animal models","volume":"25","author":"Fareed J.","year":"1999","journal-title":"Semin Thromb Hemost"},{"issue":"3","key":"e_1_2_1_10_2","first-page":"17","article-title":"Structural characteristics of low\u2010molecular\u2010weight heparins","volume":"25","author":"Casu B.","year":"1999","journal-title":"Semin Thromb Hemost"},{"issue":"3","key":"e_1_2_1_11_2","first-page":"63","article-title":"Preclinical differentiation of low molecular weight heparins","volume":"25","author":"Nader H.B.","year":"1999","journal-title":"Semin Thromb Hemost"},{"issue":"3","key":"e_1_2_1_12_2","first-page":"57","article-title":"Human pharmacokinetics of low molecular weight heparins","volume":"25","author":"Cornelli U.","year":"1999","journal-title":"Semin Thromb Hemost"},{"issue":"3","key":"e_1_2_1_13_2","first-page":"3","article-title":"Differentiation of low molecular weight heparins: applied and clinical considerations","volume":"25","author":"Fareed J.","year":"1999","journal-title":"Semin Thromb Hemost"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.114.5_Supplement.489S"},{"issue":"2","key":"e_1_2_1_15_2","first-page":"24","article-title":"Low\u2010molecular\u2010weight heparins: an overview of their pharmacodynamics, pharmacokinetics and metabolism in humans","volume":"26","author":"Frydman A.","year":"1996","journal-title":"Haemostasis"},{"issue":"1","key":"e_1_2_1_16_2","first-page":"103","article-title":"Heparin\/low molecular weight heparin and tissue pathway factor inhibitor","volume":"23","author":"Abildgaard U.","year":"1993","journal-title":"Haemostasis"},{"issue":"1","key":"e_1_2_1_17_2","first-page":"107","article-title":"Is tissue factor pathway inhibitor involved in the antithrombotic effect of heparins. Biochemical considerations","volume":"23","author":"Ostergaard P.","year":"1993","journal-title":"Haemostasis"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/0049-3848(95)00227-8"},{"key":"e_1_2_1_19_2","first-page":"799","article-title":"College of American Pathologists conference XXXI on laboratory monitoring of anticoagulant therapy. The clinical use and laboratory monitoring of low\u2010molecular\u2010weight heparin, danaparoid, hirudin and related compounds, and argatroban","volume":"122","author":"Laposata M.","year":"1998","journal-title":"Arch Pathol Lab Med"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.92.10.2819"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2257.1999.00183.x"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1614377"},{"key":"e_1_2_1_23_2","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1182\/blood.V78.9.2337.2337","article-title":"Identification of risk factors for bleeding during treatment of acute VTE with heparin or low molecular weight heparin","volume":"78","author":"Nieuwenhuis H.K.","year":"1991","journal-title":"Blood"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-996075"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.115.5.1418"},{"issue":"3","key":"e_1_2_1_26_2","first-page":"135","article-title":"Clinical differentiation of low molecular weight heparins","volume":"25","author":"Mammen E.F.","year":"1999","journal-title":"Semin Thromb Hemost"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.114.5_Supplement.531S"},{"key":"e_1_2_1_28_2","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1055\/s-0038-1650254","article-title":"Upper extremity deep venous thrombosis in cancer patients with venous access devices\u2014prophylaxis with a low\u2010molecular\u2010weight heparin (Fragmin)","volume":"75","author":"Monreal M.","year":"1996","journal-title":"Thromb Haemost"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1614319"},{"issue":"3","key":"e_1_2_1_30_2","first-page":"83","article-title":"Low molecular weight heparins in the prevention of deep\u2010vein thrombosis in general surgery","volume":"25","author":"Breddin H.K.","year":"1999","journal-title":"Semin Thromb Hemost"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1615090"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.1800800607"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)93223-A"},{"key":"e_1_2_1_34_2","first-page":"75","article-title":"Efficacy and safety of low molecular weight heparin, unfractionated heparin and warfarin for thromboembolism prophylaxis in orthopaedic surgery: a meta\u2010analysis of randomised clinical trials","volume":"27","author":"Palmer A.J.","year":"1997","journal-title":"Haemostasis"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.305.6859.913"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.159.2.137"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1613749"},{"issue":"3","key":"e_1_2_1_38_2","first-page":"73","article-title":"Venous thromboembolic prophylaxis in orthopedic surgery: knee surgery","volume":"25","author":"Planes A.","year":"1999","journal-title":"Semin Thromb Hemost"},{"issue":"3","key":"e_1_2_1_39_2","first-page":"79","article-title":"Deep\u2010vein thrombosis: prophylaxis in orthopedic surgery: hip surgery","volume":"25","author":"Lassen M.R.","year":"1999","journal-title":"Semin Thromb Hemost"},{"key":"e_1_2_1_40_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001721-199809000-00007"},{"key":"e_1_2_1_41_2","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1055\/s-0037-1614411","article-title":"Prevention of deep venous thrombosis after hip replacement. Comparison between two low\u2010molecular\u2010weight heparins, tinzaparin and enoxaparin","volume":"81","author":"Planes A.","year":"1999","journal-title":"Thromb Haemost"},{"key":"e_1_2_1_42_2","doi-asserted-by":"publisher","DOI":"10.1001\/archsurg.1993.01420150082015"},{"key":"e_1_2_1_43_2","volume-title":"Normiflo (ardeparin sodium injection) package insert","author":"Wyeth\u2010Ayerst Pharmaceuticals","year":"1998"},{"key":"e_1_2_1_44_2","volume-title":"Fragmin (dalteparin sodium injection) package insert","author":"Pharmacia & Upjohn","year":"1999"},{"key":"e_1_2_1_45_2","volume-title":"Lovenox (enoxaparin sodium injection) package insert","author":"Rh\u00f4ne\u2010Poulenc Rorer Pharmaceuticals, Inc.","year":"1998"},{"key":"e_1_2_1_46_2","first-page":"122","article-title":"Comparison of 3,000 IU aXa of the low molecular weight heparin certoparin with 5,000 IU aXa in prevention of deep vein thrombosis after total hip replacement. German thrombosis study group","volume":"18","author":"Adolf J.","year":"1999","journal-title":"Int Angiol"},{"key":"e_1_2_1_47_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-199710040-00006"},{"key":"e_1_2_1_48_2","first-page":"652","article-title":"Parnaparin. A review of its pharmacology, and clinical application in the prevention and treatment of thromboembolic and other vascular disorders","volume":"47","author":"Framptom J.E.","year":"1994","journal-title":"Drugs"},{"key":"e_1_2_1_49_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199448040-00010"},{"key":"e_1_2_1_50_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199609053351002"},{"key":"e_1_2_1_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)01453-5"},{"key":"e_1_2_1_52_2","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1055\/s-0038-1655901","article-title":"Prolonged thromboprophylaxis following hip replacement surgery\u2014results of a double\u2010blind, prospective, randomized, placebo\u2010controlled study with dalteparin (Fragmin)","volume":"77","author":"Dahl O.E.","year":"1997","journal-title":"Thromb Haemost"},{"key":"e_1_2_1_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0049-3848(98)00018-8"},{"issue":"3","key":"e_1_2_1_54_2","first-page":"97","article-title":"Low molecular weight heparins in the outpatient management of VTE","volume":"25","author":"Bick R.L.","year":"1999","journal-title":"Semin Thromb Hemost"},{"key":"e_1_2_1_55_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.114.5_Supplement.561S"},{"key":"e_1_2_1_56_2","first-page":"49","article-title":"Treatment of deep venous thrombosis with a very low molecular weight heparin fragment (CY 222)","volume":"7","author":"Janvier G.","year":"1987","journal-title":"Haemostasis"},{"issue":"1","key":"e_1_2_1_57_2","first-page":"205","article-title":"Therapeutic applications of subcutaneous low\u2010molecular\u2010weight heparin in acute venous thrombosis","volume":"20","author":"Harenberg J.","year":"1990","journal-title":"Haemostasis"},{"key":"e_1_2_1_58_2","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1055\/s-0038-1647348","article-title":"Two daily subcutaneous injections of Fragmin as compared with intravenous standard heparin in the treatment of deep venous thrombosis (DVT)","volume":"64","author":"Bratt G.","year":"1990","journal-title":"Thromb Haemost"},{"issue":"1","key":"e_1_2_1_59_2","first-page":"220","article-title":"Treatment of deep venous thrombosis by fixed doses of a low\u2010molecular\u2010weight heparin (CY 216)","volume":"20","author":"Prandoni P.","year":"1990","journal-title":"Haemostasis"},{"key":"e_1_2_1_60_2","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1055\/s-0038-1647660","article-title":"A randomized trial of subcutaneous low molecular weight heparin (CY 216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis. A collaborative European multicentre study","volume":"65","year":"1991","journal-title":"Thromb Haemost"},{"key":"e_1_2_1_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)91054-C"},{"key":"e_1_2_1_62_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199204093261502"},{"key":"e_1_2_1_63_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1993.00410130045005"},{"key":"e_1_2_1_64_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1648836"},{"key":"e_1_2_1_65_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199603143341102"},{"key":"e_1_2_1_66_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2796.1996.18845000.x"},{"key":"e_1_2_1_67_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199709043371001"},{"key":"e_1_2_1_68_2","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1055\/s-0038-1650553","article-title":"Once\u2010daily subcutaneous dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis","volume":"76","author":"Fiessinger J.N.","year":"1996","journal-title":"Thromb Haemost"},{"key":"e_1_2_1_69_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.158.21.2325"},{"key":"e_1_2_1_70_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00280041"},{"key":"e_1_2_1_71_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199603143341101"},{"key":"e_1_2_1_72_2","doi-asserted-by":"publisher","DOI":"10.1016\/0049-3848(89)90307-1"},{"key":"e_1_2_1_73_2","doi-asserted-by":"publisher","DOI":"10.1016\/0049-3848(92)90257-B"},{"key":"e_1_2_1_74_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0741-5214(96)70012-5"},{"key":"e_1_2_1_75_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1642507"},{"key":"e_1_2_1_76_2","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1055\/s-0037-1615089","article-title":"Comparison of a once daily with a twice daily subcutaneous low molecular weight heparin regimen in the treatment of deep vein thrombosis","volume":"79","author":"Charbonnier B.A.","year":"1998","journal-title":"Thromb Haemost"},{"key":"e_1_2_1_77_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.309.6950.299"},{"key":"e_1_2_1_78_2","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1001\/archinte.1995.00430060059007","article-title":"Treatment of deep venous thrombosis with low\u2010molecular\u2010weight heparins. A meta\u2010analysis","volume":"155","author":"Lensing A.W.A.","year":"1995","journal-title":"Arch Intern Med"},{"key":"e_1_2_1_79_2","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1055\/s-0038-1642702","article-title":"Low molecular weight heparins (LMWH) in the treatment of patients with acute VTE","volume":"74","author":"Hirsh J.","year":"1995","journal-title":"Thromb Haemost"},{"key":"e_1_2_1_80_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(97)89484-3"},{"key":"e_1_2_1_81_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-130-10-199905180-00003"},{"key":"e_1_2_1_82_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-130-10-199905180-00002"},{"issue":"3","key":"e_1_2_1_83_2","first-page":"8","article-title":"The economic impact of treating deep venous thrombosis with low\u2010molecular\u2010weight heparin: outcome of therapy and health economy aspects","volume":"28","author":"Hull R.D.","year":"1998","journal-title":"Haemostasis"},{"key":"e_1_2_1_84_2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1055\/s-0038-1642376","article-title":"Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with VTE and contraindications to coumarin","volume":"71","author":"Monreal M.","year":"1994","journal-title":"Thromb Haemost"},{"key":"e_1_2_1_85_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1614412"},{"key":"e_1_2_1_86_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0741-5214(99)70139-4"},{"key":"e_1_2_1_87_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.85.4.1380"},{"key":"e_1_2_1_88_2","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1055\/s-0038-1649960","article-title":"Subcutaneous low\u2010molecular\u2010weight heparin Fragmin versus intravenous unfractionated heparin in the treatment of acute non massive pulmonary embolism: an open randomized pilot study","volume":"74","author":"Meyer G.","year":"1995","journal-title":"Thromb Haemost"},{"key":"e_1_2_1_89_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199709043371002"},{"issue":"3","key":"e_1_2_1_90_2","first-page":"107","article-title":"Differentiation of low molecular weight heparins in treatment of acute deep vein thrombosis","volume":"25","author":"Davidson B.L.","year":"1999","journal-title":"Semin Thromb Hemost"},{"key":"e_1_2_1_91_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.19.14.155S.31704"},{"key":"e_1_2_1_92_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.114.5_Supplement.611S"},{"key":"e_1_2_1_93_2","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(95)80001-W"},{"key":"e_1_2_1_94_2","doi-asserted-by":"publisher","DOI":"10.1053\/euhj.1999.1879"},{"key":"e_1_2_1_95_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.96.1.61"},{"key":"e_1_2_1_96_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)91270-2"},{"key":"e_1_2_1_97_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.100.15.1593"},{"key":"e_1_2_1_98_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199708143370702"},{"key":"e_1_2_1_99_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.100.15.1602"},{"key":"e_1_2_1_100_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.97.17.1702"},{"issue":"3","key":"e_1_2_1_101_2","first-page":"113","article-title":"Low molecular weight heparins in the management of unstable angina\/non\u2010Q\u2010wave myocardial infarction","volume":"25","author":"Cohen M.","year":"1999","journal-title":"Semin Thromb Hemost"},{"key":"e_1_2_1_102_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.159.16.1849"},{"issue":"1","key":"e_1_2_1_103_2","first-page":"107","article-title":"Principal view on dose adjustment of low molecular weight heparins","volume":"19","author":"Bergqvist D.","year":"1993","journal-title":"Semin Thromb Hemost"},{"issue":"1","key":"e_1_2_1_104_2","first-page":"89","article-title":"Factor Xa inhibition: correlation between the plasma levels of anti\u2010Xa activity and occurrence of thrombosis and haemorrhage","volume":"23","author":"Leizorovicz A.","year":"1993","journal-title":"Haemostasis"},{"key":"e_1_2_1_105_2","first-page":"977","article-title":"Relation between weight, obesity, and frequency of deep venous thrombosis after enoxaparin in orthopedic surgery [abstr]","volume":"73","author":"Samama M.M.","year":"1995","journal-title":"Thromb Haemost"},{"issue":"2","key":"e_1_2_1_106_2","first-page":"102S","article-title":"Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults\u2010the evidence report. Treatment guidelines","volume":"6","author":"National Institutes of Health National Heart Lung and Blood Institute","year":"1998","journal-title":"Obesity Res."},{"key":"e_1_2_1_107_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0049-3848(98)00083-8"},{"key":"e_1_2_1_108_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.114.5_Supplement.445S"},{"key":"e_1_2_1_109_2","doi-asserted-by":"publisher","DOI":"10.1016\/0049-3848(86)90039-3"},{"key":"e_1_2_1_110_2","doi-asserted-by":"publisher","DOI":"10.1016\/0049-3848(91)90134-I"},{"key":"e_1_2_1_111_2","doi-asserted-by":"publisher","DOI":"10.1016\/0049-3848(91)90141-I"},{"key":"e_1_2_1_112_2","doi-asserted-by":"publisher","DOI":"10.1159\/000186641"},{"key":"e_1_2_1_113_2","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1055\/s-0037-1615034","article-title":"Aging and VTE influence the pharmacodynamics of the anti\u2010Xa and anti\u2010thrombin activities of a low molecular weight heparin (nadroparin)","volume":"79","author":"Mismetti P.","year":"1998","journal-title":"Thromb Haemost"},{"key":"e_1_2_1_114_2","first-page":"1192","article-title":"A comparison of adverse effects of enoxaparin in patients with renal insufficiency versus normal renal function [abstr]","volume":"19","author":"Gerlach A.T.","year":"1999","journal-title":"Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"},{"key":"e_1_2_1_115_2","doi-asserted-by":"publisher","DOI":"10.1159\/000013359"},{"key":"e_1_2_1_116_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199607113350207"},{"key":"e_1_2_1_117_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8545(05)70319-3"},{"key":"e_1_2_1_118_2","doi-asserted-by":"publisher","DOI":"10.1097\/00003081-199603000-00009"},{"issue":"1","key":"e_1_2_1_119_2","first-page":"55","article-title":"Anticoagulant therapy during pregnancy: an update","volume":"24","author":"Dizon\u2010Townson D.","year":"1998","journal-title":"Semin Thromb Hemost"},{"key":"e_1_2_1_120_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0020-7292(99)80040-X"},{"key":"e_1_2_1_121_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.19.13.1013.31588"},{"key":"e_1_2_1_122_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0049-3848(99)00110-3"},{"key":"e_1_2_1_123_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9378(99)70091-8"},{"key":"e_1_2_1_124_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V83.5.1251.1251"},{"key":"e_1_2_1_125_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1055\/s-0038-1657492","article-title":"Thrombosis in the young: epidemiology and risk factors. A focus on venous thrombosis","volume":"78","author":"Rosendaal F.R.","year":"1997","journal-title":"Thromb Haemost"},{"key":"e_1_2_1_126_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(98)70343-9"},{"key":"e_1_2_1_127_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.114.5_Supplement.748S"},{"key":"e_1_2_1_128_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(96)70273-1"},{"key":"e_1_2_1_129_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.55.12.1533"},{"key":"e_1_2_1_130_2","first-page":"282","article-title":"A nomogram to establish therapeutic levels of the low\u2010molecular\u2010weight heparin (LMWH), clivarine in children requiring treatment for VTE [abstr]","volume":"77","author":"Massicotte M.P.","year":"1997","journal-title":"Thromb Haemost"},{"key":"e_1_2_1_131_2","doi-asserted-by":"publisher","DOI":"10.1007\/PL00014339"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.21.2.218.34112","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.21.2.218.34112","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:25:00Z","timestamp":1761049500000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.21.2.218.34112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,2]]},"references-count":130,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2001,2]]}},"alternative-id":["10.1592\/phco.21.2.218.34112"],"URL":"https:\/\/doi.org\/10.1592\/phco.21.2.218.34112","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,2]]},"assertion":[{"value":"2012-01-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}